The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.
about
Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfallsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting.CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity.Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel.Plaque distribution in clopidogrel responders and low responders as determined by multislice computed tomography.The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction.Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapyInterplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.Is there attenuation of benefit of invasive therapy in patients with chronic kidney disease? Results from randomized trials and registry data.Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary interventionAspirin for primary prevention of cardiovascular disease in diabetes mellitusEvaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE).Impact of platelet function test on platelet responsiveness and clinical outcome after coronary stent implantation: platelet responsiveness and clinical outcome.Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han populationClinical presentations, antiplatelet strategies and prognosis of patients with stent thrombosis: an observational study of 140 patients.State of the art in platelet function testing.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoClinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.Clopidogrel in acute coronary syndrome: implications of recent study findings.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.Genetic and non-genetic factors affecting the response to clopidogrel therapy.Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Personalizing antiplatelet therapy with clopidogrel.Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.Monitoring aspirin and clopidogrel response: testing controversies and recommendations.Cigarette smoking and clopidogrel interaction.Genetics of platelet inhibitor treatmentResistance to antiplatelet drugs: what progress has been made?Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.Impact of tailored anti-P2Y12 therapies in acute coronary syndromes.Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics.Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping.Determinants to optimize response to clopidogrel in acute coronary syndrome
P2860
Q26775125-4166502B-D708-4F64-894A-4F47804B682BQ26801867-D4AB05F3-C00F-43E9-81B9-D2A2E41638F3Q30877943-5495867A-F3AE-4DE8-AB91-01C083A69D41Q33368192-79B27245-BDA8-4B53-9CDC-2668A37B2E62Q33516375-5BBB4343-045B-4A4D-97B9-8B1007ED01CAQ33569289-63B64D88-C349-4D15-A0D3-D1EB9F2DE4EFQ33729410-17F91722-1A1C-4E43-8D67-88A0DA0EC3B6Q33751281-92BB463B-9067-49EB-8F16-CD9FD5088470Q33791290-E49C175F-97D1-4037-9EA0-0A7D0CB9B6E9Q33933475-3DA0A025-5BDE-4713-A396-87C37E8B71AFQ34283808-058BD42B-8453-479B-9F0D-32D7E173374FQ34726838-78CAD90B-D628-40BB-A485-9B8692A6D698Q35132896-843FDB7B-4D18-4BA7-9CB0-D07465610CB5Q35208684-ED4F3EC1-C428-4D7D-8929-2F9A715798E1Q36078210-257E8239-05E0-419B-B2A4-6796AC177268Q36216424-3B6415D3-59CA-4EA5-A45E-EEA4B24B6899Q36328226-26DCE22F-B7F4-448A-BDE7-14817CAC97D8Q36360516-74FC0A05-7B3A-4B29-B425-EC3A69D28B30Q36802971-7C661C87-49A5-48B3-B8F6-4BC6FB828472Q37378896-1D588AD5-4919-4D79-9EE6-FEC39DC460C5Q37506535-F47E59F8-8DF8-4C0D-85CD-B1683FE59E1FQ37627874-4D7D6E4B-902C-4747-AD28-5F74FB2AA0CFQ37693951-3E53D557-5508-492F-9C6B-8D07ADDD060CQ37786639-8519E0BE-6743-46EC-B497-BEC5D235625BQ37882712-750F0656-95F3-4AE7-8BD2-1F5630CC7ED1Q37923969-52BE7877-6DCC-4EA3-9EC4-2733D5934E31Q37991382-B2FD0956-6EE9-43E7-8F9C-99704A874E40Q38012079-BA57F02F-3E15-4340-9138-4DD28EF0CFC3Q38040698-882981C5-B391-4624-920D-E0D16294DE5AQ38087381-8E8D38BA-01BF-4CD9-9C9B-9BEB7EC7F79BQ38099235-022F7946-B879-434F-A610-487991374490Q38099541-975D39BF-DA33-4F0F-A372-C53B87FB0591Q38131848-8B0EC185-5AC3-4C31-BA1E-D18F5EA37BD8Q38258270-B98530BF-AA8E-446B-BF07-CA94511EBA00Q38380508-5F1AB545-DD20-4832-A550-4B5F4C438D32Q38444425-55DC6ED1-C2EE-4261-9EA3-34F3ACC2B945Q38456752-CCE11DDD-E0EA-43B9-8C49-4A4133D04402Q39249688-A9BA1947-E72F-4700-BF75-5376A0CCAD08Q40498149-B06F7D7B-B960-4A05-85B0-647E0908C183Q41848961-F8CF9A5D-B4BB-489E-9993-8047BE424CA5
P2860
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The Residual Platelet Aggregat ...... oronary Stent (PREDICT) score.
@ast
The Residual Platelet Aggregat ...... oronary Stent (PREDICT) score.
@en
The Residual Platelet Aggregation after Deployment of Intracoronary Stent
@nl
type
label
The Residual Platelet Aggregat ...... oronary Stent (PREDICT) score.
@ast
The Residual Platelet Aggregat ...... oronary Stent (PREDICT) score.
@en
The Residual Platelet Aggregation after Deployment of Intracoronary Stent
@nl
prefLabel
The Residual Platelet Aggregat ...... oronary Stent (PREDICT) score.
@ast
The Residual Platelet Aggregat ...... oronary Stent (PREDICT) score.
@en
The Residual Platelet Aggregation after Deployment of Intracoronary Stent
@nl
P2093
P1476
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score
@en
P2093
P356
10.1111/J.1538-7836.2007.02812.X
P577
2007-10-22T00:00:00Z